Jak planuję hormonoterapię u chorego z rakiem gruczołu krokowego – spojrzenie eksperta Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2011
Słowa kluczowe:
rak gruczołu krokowego, hormonoterapia neoadiuwantowa, uzupełniająca, zmiany przerzutowe
##plugins.themes.bootstrap3.article.main##
Abstrakt
Rak gruczołu krokowego w ciągu ostatnich kilkudziesięciu lat stał się jednym z najczęstszych nowotworów u mężczyzn oraz jedną z głównych przyczyn zgonów na nowotwory. Ponieważ jest nowotworem hormonozależnym, od lat 40. XX wieku leczy się go przy użyciu preparatów hormonalnych. Obecnie najczęściej stosowana jest blokada hormonalna z użyciem analogów LHRH w leczeniu przerzutowego raka gruczołu krokowego. Terapia hormonalna może być stosowana w wielu etapach leczenia tego nowotworu, od leczenia neoadiuwantowego przed radioterapią, uzupełniającego po radioterapii lub leczeniu operacyjnym, do leczenia po niepowodzeniach terapii radykalnych. Po progresji po leczeniu hormonalnym możliwe jest uzyskanie odpowiedzi terapeutycznej na leczenie kolejnego rzutu.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.generic.paperbuzz.metrics##
##plugins.generic.paperbuzz.loading##
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Poborski W. Jak planuję hormonoterapię u chorego z rakiem gruczołu krokowego – spojrzenie eksperta. OncoReview [Internet]. 30 wrzesień 2011 [cytowane 23 listopad 2024];1(3(3):184-9. Dostępne na: https://journalsmededu.pl/index.php/OncoReview/article/view/256
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Krajowy Rejestr Nowotworów. Centrum Onkologii – Instytut M. Skłodowskiej-Curie.
2. Dobruch J., Modzelewska E., Popiel M. et al.: Stopień klinicznego zaawansowania raka stercza w momencie rozpoznania. Urol. Pol. 2006; 59: 269-274.
3. Huggins C., Hodges C.V.: Studies on prostatic cancer. The effects of castration, of estrogen and of androgen injectionon serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293-297.
4. D’Amico A.V., Whittington R., Malkowicz S.B. et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstinal radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.
5. Pilepich M.V., Vinter K., John M. et al.: Phase III radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definite radiotherapy in locally advanced carcionoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 2001; 50: 1243-1252.
6. Hanks G.E., Pajak T.F., Porter A. et al.: Phase II trial on long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate ; the Radiation Therapy Oncology Group Protocol 92 02. J. Clin. Oncol. 2003; 21: 3972-3978.
7. Lawton C.A., Winter K., Grignon D. et al.: Androgen suppression plus radiation versus radiation alone for patients with stage d1/pathologic nodepositive adenocarcinoma of the prostate; updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J. Clin. Oncol. 2005; 23: 800-807.
8. Eisenberger M.A., Blumenstein B.A., Crawford E.D.: Bilateral orchidectomy with or without flutamide for metastatic prostate cancer. N. Eng. J. Med. 1998; 339: 1036-1042.
9. Sato N., Gleave M.E., Bruchovsky N. et al.: Intermittent androgen suppression delays progression to androgen independent regulation of prostatespecyfic antigen gene in the LNCaP prostate tumor model. J. Steroid. Biochem. Mol. Biol. 1996; 58: 139-146.
10. Show G.L., Wilson P., Curick J. et al.: International study into the use of intermittent hormonal therapy in the treatment of carcinoma of the prostate; a meta-analysis of 1446 patients. BJU Int. 2007; 99: 1056-1065.
11. Omstein D.K., Rao G., Johnson B.: Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 1996; 48: 901-905.
12. Brufsky A., Fontaine-Roth P., Berlane K.: Finasteryde and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 1997; 49: 913-920.
13. Byar D.P., Carele D.K.: Hormone therapy for prostate cancer; results of the Veteran Administration Cooperative Urological Reaserch Group studies NCI Monographs 1988; 7: 165-170.
14. Schroder F.H., Kurth K.H., Fossa S.D.: Early versus delayded endocrine treatment of pN1-3M0 prostate cancer without local traearment of the primary tumor; results of the European Organisation for the Reaserch and Treatment of Cancer 30846 – a phase III study. J. Urol. 2004; 172: 923-927.
15. Hussan M., Tangen C.M., Higano C. et al.: Absolute prostate-specyfic antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). J. Clin. Oncol. 2006; 24: 3984-3990.
16. Cradford E.D., Sartor O., Chu F. et al.: A 12-month clinical study of LA2585 (45.0mg): a new 6 month subcutaneous delivery system for leuproide acetate for the treatment of prostate cancer. J. Urol. 2006; 175: 533-536.
17. Oh W.K., Manola J., Bittmann L. et al.: Finasteryde and Flutamide therapy in patients with advanced prostate cancer: response to subsequent castration et long-term follow up. Urology 2003; 62: 99-104.
18. Hussain M., Wolf M., Marshall E. et al.: Effect of continued androgen deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer; a Southwest Oncology Group report. J. Clin. Oncol. 1994; 12: 1868-1875.
19. Taylor C.D., Elson P., Trump D.L.: Importance of continued testicular suppression In the hormone-refractory prostate cance. J. Clin. Oncol. 1993; 11: 2167-72.
20. Dupont A., Gomez J.l., Cusan L. et al.: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol. 1993; 3: 908-913.
21. Tannock L., Gospodarowicy M., Meakin W. et al.: Treatment of metastatic prostatic cancer with low dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J. Clin. Oncol. 1989; 7: 590-597.
22. Ryan C.J., Small E.J.: Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology 2003; 62(supl. 1): 87-94.
23. Lam J.S., Leppert J.T., Vernulapalii S.N. et al.: Secondary hormonal therapy for advanced prostate cancer. J. Urol. 2006; 175: 27-34.
24. Figg W.D., Liu Y., Arlen P. et al.: A randomized, phase II trial of ketoconazole plus aledronate versus ketoconazole alone in patients with androgene independent prostate cancer and bone metastases. J. Urol. 2005; 173: 790-796.
25. Ryan C.J., Harzstark A.L., Lin A.M. et al.: Abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC) and prior therapy with ketoconazole: A Prostate Cancer Clinical Trials Consortium study. J. Clin. Oncol. 2011; 29(supl.): abstr. 4500.
26. Senkus-Konefka E., Antoniewicz A., Borkowska A. et al.: Zalecenia dotyczące postępowania w raku gruczołu krokowego – konferencja okrągłego stołu. Onkol. Prak. Klin. 2007; 3: 103-11.
2. Dobruch J., Modzelewska E., Popiel M. et al.: Stopień klinicznego zaawansowania raka stercza w momencie rozpoznania. Urol. Pol. 2006; 59: 269-274.
3. Huggins C., Hodges C.V.: Studies on prostatic cancer. The effects of castration, of estrogen and of androgen injectionon serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293-297.
4. D’Amico A.V., Whittington R., Malkowicz S.B. et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstinal radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.
5. Pilepich M.V., Vinter K., John M. et al.: Phase III radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definite radiotherapy in locally advanced carcionoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 2001; 50: 1243-1252.
6. Hanks G.E., Pajak T.F., Porter A. et al.: Phase II trial on long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate ; the Radiation Therapy Oncology Group Protocol 92 02. J. Clin. Oncol. 2003; 21: 3972-3978.
7. Lawton C.A., Winter K., Grignon D. et al.: Androgen suppression plus radiation versus radiation alone for patients with stage d1/pathologic nodepositive adenocarcinoma of the prostate; updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J. Clin. Oncol. 2005; 23: 800-807.
8. Eisenberger M.A., Blumenstein B.A., Crawford E.D.: Bilateral orchidectomy with or without flutamide for metastatic prostate cancer. N. Eng. J. Med. 1998; 339: 1036-1042.
9. Sato N., Gleave M.E., Bruchovsky N. et al.: Intermittent androgen suppression delays progression to androgen independent regulation of prostatespecyfic antigen gene in the LNCaP prostate tumor model. J. Steroid. Biochem. Mol. Biol. 1996; 58: 139-146.
10. Show G.L., Wilson P., Curick J. et al.: International study into the use of intermittent hormonal therapy in the treatment of carcinoma of the prostate; a meta-analysis of 1446 patients. BJU Int. 2007; 99: 1056-1065.
11. Omstein D.K., Rao G., Johnson B.: Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 1996; 48: 901-905.
12. Brufsky A., Fontaine-Roth P., Berlane K.: Finasteryde and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 1997; 49: 913-920.
13. Byar D.P., Carele D.K.: Hormone therapy for prostate cancer; results of the Veteran Administration Cooperative Urological Reaserch Group studies NCI Monographs 1988; 7: 165-170.
14. Schroder F.H., Kurth K.H., Fossa S.D.: Early versus delayded endocrine treatment of pN1-3M0 prostate cancer without local traearment of the primary tumor; results of the European Organisation for the Reaserch and Treatment of Cancer 30846 – a phase III study. J. Urol. 2004; 172: 923-927.
15. Hussan M., Tangen C.M., Higano C. et al.: Absolute prostate-specyfic antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). J. Clin. Oncol. 2006; 24: 3984-3990.
16. Cradford E.D., Sartor O., Chu F. et al.: A 12-month clinical study of LA2585 (45.0mg): a new 6 month subcutaneous delivery system for leuproide acetate for the treatment of prostate cancer. J. Urol. 2006; 175: 533-536.
17. Oh W.K., Manola J., Bittmann L. et al.: Finasteryde and Flutamide therapy in patients with advanced prostate cancer: response to subsequent castration et long-term follow up. Urology 2003; 62: 99-104.
18. Hussain M., Wolf M., Marshall E. et al.: Effect of continued androgen deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer; a Southwest Oncology Group report. J. Clin. Oncol. 1994; 12: 1868-1875.
19. Taylor C.D., Elson P., Trump D.L.: Importance of continued testicular suppression In the hormone-refractory prostate cance. J. Clin. Oncol. 1993; 11: 2167-72.
20. Dupont A., Gomez J.l., Cusan L. et al.: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol. 1993; 3: 908-913.
21. Tannock L., Gospodarowicy M., Meakin W. et al.: Treatment of metastatic prostatic cancer with low dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J. Clin. Oncol. 1989; 7: 590-597.
22. Ryan C.J., Small E.J.: Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology 2003; 62(supl. 1): 87-94.
23. Lam J.S., Leppert J.T., Vernulapalii S.N. et al.: Secondary hormonal therapy for advanced prostate cancer. J. Urol. 2006; 175: 27-34.
24. Figg W.D., Liu Y., Arlen P. et al.: A randomized, phase II trial of ketoconazole plus aledronate versus ketoconazole alone in patients with androgene independent prostate cancer and bone metastases. J. Urol. 2005; 173: 790-796.
25. Ryan C.J., Harzstark A.L., Lin A.M. et al.: Abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC) and prior therapy with ketoconazole: A Prostate Cancer Clinical Trials Consortium study. J. Clin. Oncol. 2011; 29(supl.): abstr. 4500.
26. Senkus-Konefka E., Antoniewicz A., Borkowska A. et al.: Zalecenia dotyczące postępowania w raku gruczołu krokowego – konferencja okrągłego stołu. Onkol. Prak. Klin. 2007; 3: 103-11.